New Frontiers: Procedures to Tackle Resistant Hypertension
New Frontiers: Procedures to Tackle Resistant Hypertension
Innovative Solutions
When medications aren't enough, innovative procedures offer new hope for those battling resistant hypertension. Explore the latest options available.
Contents
- Renal Denervation: A Cutting-Edge Therapy
- Baroreflex Activation Therapy
- Considering the Risks and Benefits
Renal Denervation: A Cutting-Edge Therapy
Renal denervation targets nerves in the kidneys to reduce blood pressure. This minimally invasive procedure can be particularly helpful for patients who don't respond well to medications. Several studies have shown its potential in lowering blood pressure, although it's not yet widely available.
Baroreflex Activation Therapy
Baroreflex Activation Therapy involves implanting a device that stimulates the carotid baroreceptors to control blood pressure. Initial trials indicate this therapy can lead to significant blood pressure reductions. However, it's still in the experimental stage and not yet approved in many countries.
Considering the Risks and Benefits
While these procedures offer hope, they come with potential risks like nerve injury or fluid retention. Careful evaluation and consultation with healthcare providers are essential. These procedures are usually considered when other treatment options have failed.
FAQs
What is renal denervation?
It's a procedure targeting kidney nerves to lower blood pressure.
How does Baroreflex Activation Therapy work?
It uses a device to stimulate carotid baroreceptors, reducing blood pressure.
Are there risks with these procedures?
Yes, potential risks include nerve injury and fluid retention.
Are these procedures widely available?
They are still experimental and not approved in all regions.
Innovative Insights
While promising, these procedures should be considered carefully alongside traditional treatments.
Additional References
- Bhatt DL, Vaduganathan M, Kandzari DE, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet 2022; 400:1405.
- Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011; 58:765.
This article has been reviewed for accuracy by one of the licensed medical doctors working for Doctronic.